STOCK TITAN

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.

Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.

The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.

Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.

Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.

This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.

Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced significant executive appointments aimed at advancing its commercialization efforts in psoriasis and liver cancer. Dr. Pnina Fishman has been appointed as Executive Chairman of the Board, maintaining her role as Chief Scientific Officer. Motti Farbstein, who has been with the company for 20 years, will take over as Chief Executive Officer while continuing his duties as Chief Financial Officer. These changes will be effective from June 30, 2023. The company is pushing forward with two pivotal Phase III trials for its drug candidates, Piclidenoson for psoriasis and Namodenoson for liver cancer. Can-Fite's prospects in the market are substantial, with ongoing evaluations and regulatory designations for its drugs, aimed at addressing major health conditions and tapping into multi-billion dollar markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its registration plan for a pivotal Phase III clinical trial targeting moderate to severe psoriasis. The trial will evaluate the safety and efficacy of Piclidenoson, the company's lead drug candidate. This follows the recent successful topline results from the Phase III COMFORT™ study, which demonstrated significant improvement over placebo. Can-Fite is also preparing a comparable data package for the US FDA. The CEO emphasized the drug's oral dosage, safety profile, and potential in a large market for effective psoriasis treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced its financial results for the year ended December 31, 2022, reporting revenues of $0.81 million, a 4.7% decrease from $0.85 million in 2021. Research and development expenses decreased by 21.2% to $7.76 million, while general and administrative expenses fell 18.2% to $3.14 million. The net loss was reduced to $10.17 million from $12.61 million in 2021. Can-Fite highlighted significant clinical achievements, including a successful Phase III trial for Piclidenoson in psoriasis and promising preclinical results for Namodenoson against pancreatic cancer. The company also secured a patent for liver fibrosis treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced regional deals that include upfront payments, regulatory and sales milestones, and double-digit royalties. The company's VP of Business Development, Dr. Sari Fishman, will participate in the BIO-Europe Spring conference in Basel, Switzerland from March 20 to 22, 2023, aiming to establish licensing and distribution agreements for its advanced drug candidates, Piclidenoson and Namodenoson. Both drugs have shown promising results in clinical trials, with Piclidenoson moving into a Phase III trial. Can-Fite aims to accelerate drug distribution, enhancing partnership agreements in Europe, Asia, and Canada.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced compassionate use of its drug Namodenoson for patients with decompensated cirrhosis at Soroka Medical Center in Israel. This condition currently has no approved therapeutic options aside from liver transplants. Namodenoson, undergoing pivotal Phase III studies for liver cancer, has shown potential benefits in clinical trials for cirrhosis and NASH, highlighting the urgent need for effective treatments as the liver cirrhosis market is projected to reach $15 billion in the U.S. by 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced progress on its drug Namodenoson, currently undergoing a pivotal Phase III study approved by the FDA and EMA. Namodenoson, an orally bioavailable drug, targets liver cancer cells while sparing normal liver cells, demonstrating improved survival rates in advanced liver cancer patients. The drug holds Orphan Drug and Fast Track designations in both the U.S. and Europe. Published research indicates a very favorable safety profile and its potential effectiveness based on Phase II trial outcomes. The study aims to enroll 450 patients across Israel, Europe, and the U.S., with an interim data analysis planned.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
none
Rhea-AI Summary

Can-Fite BioPharma (NYSE: CANF) announced that its anti-cancer drug, Namodenoson, exhibits significant inhibition of pancreatic carcinoma growth, both alone and in combination with gemcitabine, the standard chemotherapy. These pre-clinical studies highlighted Namodenoson's excellent safety profile and potential effectiveness against pancreatic cancer, a disease with a bleak 11% 5-year survival rate in the U.S. The company has filed a patent application for Namodenoson aimed at treating this aggressive cancer. The global pancreatic cancer therapeutics market was valued at approximately $3.6 billion in 2021 and is projected to grow significantly by 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced definitive agreements for a registered direct offering of 1,000,000 American Depositary Shares (ADSs) at $5.50 each, expected to yield approximately $7.5 million, alongside a private placement of 363,637 ADSs at the same price. The offerings include Series A warrants with an exercise price of $6.00 and Series B warrants at $5.50. Proceeds will fund R&D and clinical trials. The closing is anticipated by January 13, 2023, and the warrants will have a term of up to 5.5 years and 20 months respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
-
Rhea-AI Summary

Can-Fite BioPharma has submitted a market registration plan for its lead drug candidate, Piclidenoson, to the European Medicines Agency. This follows successful topline results from the Phase III COMFORT study, which showed significant improvement over placebo in treating moderate to severe psoriasis. The drug boasts a superior safety profile compared to Otezla, the leading oral psoriasis therapy. With a focus on the $26 billion psoriasis market, Can-Fite aims to position Piclidenoson as a preferred treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
News
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced a change to its American Depositary Shares (ADSs) ratio, effective January 9, 2023. The new ratio will be one ADS representing 300 ordinary shares, equivalent to a one-for-ten reverse split. Existing ADS holders will exchange ten ADSs for one new ADS. There will be no changes to ordinary shares, and the new ADSs will continue trading under the symbol 'CANF'. Following this, the ADS price is expected to increase proportionally, though there's no guarantee of reaching ten times the previous price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none

FAQ

What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is $1.48 as of December 20, 2024.

What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is approximately 8.8M.

What does Can-Fite BioPharma Ltd. specialize in?

Can-Fite BioPharma specializes in developing orally bioavailable small molecule therapeutic products for cancer, liver, and inflammatory diseases.

Where is Can-Fite BioPharma Ltd. located?

Can-Fite BioPharma Ltd. is headquartered at 10 Bareket Street, פ"ת, Israel.

What is Piclidenoson?

Piclidenoson is a drug candidate from Can-Fite BioPharma currently in Phase III clinical trials for treating psoriasis.

What is Namodenoson used for?

Namodenoson is aimed at treating liver conditions such as hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH).

What stage are the trials for Namodenoson?

Namodenoson is in a Phase III trial for HCC and a Phase IIb trial for NASH.

What is the A3 adenosine receptor (A3AR)?

The A3 adenosine receptor (A3AR) is a therapeutic target used by Can-Fite BioPharma's platform technology for drug development.

How does Can-Fite BioPharma's technology benefit patients?

Can-Fite BioPharma's technology focuses on developing oral therapeutics, which are easier to administer, potentially improving patient compliance and treatment outcomes.

What is the significance of Can-Fite BioPharma's partnerships?

Partnerships with research institutions and other entities help Can-Fite BioPharma advance its drug development programs and bring innovative therapies to market.

Is Can-Fite BioPharma listed on any stock exchange?

Yes, Can-Fite BioPharma Ltd. is listed on NASDAQ under the symbol CANF.

What is the focus of Can-Fite BioPharma's current projects?

The current focus includes advanced clinical trials for drugs treating psoriasis, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH).

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares

NYSE:CANF

CANF Rankings

CANF Stock Data

8.84M
6.10M
10.5%
2.27%
Biotechnology
Healthcare
Link
United States of America
Ramat Gan